Suppr超能文献

在 COVID-19 期间,注射用填充物引起的急性炎症反应发生率增加。

Increase in the incidence of acute inflammatory reactions to injectable fillers during COVID-19 era.

机构信息

Azabu Beauty Clinic, Tokyo, Japan.

Jyosui Dermatology Clinic, Fukuoka, Japan.

出版信息

J Cosmet Dermatol. 2022 May;21(5):1816-1821. doi: 10.1111/jocd.14886. Epub 2022 Mar 12.

Abstract

BACKGROUND

Acute inflammatory reactions (AIRs) are a rare complication following esthetic treatment with hyaluronic acid (HA) and/or human collagen fillers. However, a substantial increase in the frequency of AIRs was observed in the first author's clinic since May 2020.

AIMS

To report AIR cases, we experienced and discuss potential underlying mechanisms.

METHODS

This was a retrospective review of patients representing AIR symptoms following filler injection with HA or human collagen in our clinic.

RESULTS

Although only one case of an AIR with an incidence rate of 0.01% was recorded following filler treatment between September 2008 and April 2020 in our clinic, we observed 14 AIR cases without anaphylaxis, with an incidence rate of 1.18% between May 2020 and June 2021, in line with the spreading of the new coronavirus pandemic. All cases were females aged 40-57 years, and the time of onset was within hours after filler injection. Three patients had been treated with HA fillers only, 2 with HA plus human collagen, and 9 with human collagen only. Most patients had been treated with these products in the past. Nine patients were treated with oral prednisolone. In all cases, symptoms resolved entirely within a week without sequelae.

CONCLUSIONS

The marked increase in AIRs coincided with the COVID-19 pandemic. Possible explanations include immune system alterations caused by extensive changes in domestic and personal hygiene, prolonged and elevated stress levels, and subclinical COVID-19 infection. Further studies may be warranted.

摘要

背景

急性炎症反应(AIRs)是使用透明质酸(HA)和/或人体胶原蛋白填充剂进行美容治疗的罕见并发症。然而,自 2020 年 5 月以来,我们发现 AIR 的发生频率显著增加。

目的

报告我们遇到的 AIR 病例,并讨论潜在的发病机制。

方法

这是对我们诊所中因 HA 或人体胶原蛋白填充剂注射而出现 AIR 症状的患者进行的回顾性研究。

结果

尽管我们在 2008 年 9 月至 2020 年 4 月期间的填充治疗中仅记录到一例 AIR 发生率为 0.01%的病例,但我们观察到 2020 年 5 月至 2021 年 6 月期间,14 例无过敏反应的 AIR 病例,发生率为 1.18%,这与新冠病毒大流行的传播一致。所有病例均为 40-57 岁女性,发病时间均在填充后数小时内。其中 3 例仅接受过 HA 填充剂治疗,2 例接受过 HA 加人体胶原蛋白治疗,9 例仅接受过人体胶原蛋白治疗。大多数患者过去曾接受过这些产品的治疗。9 例患者接受了口服泼尼松龙治疗。所有患者的症状均在一周内完全缓解,无后遗症。

结论

AIR 发生率的显著增加与 COVID-19 大流行同时发生。可能的解释包括国内和个人卫生习惯的广泛改变引起的免疫系统改变、长期和升高的压力水平以及亚临床 COVID-19 感染。可能需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fa4/9115292/38fec8f3f9c1/JOCD-21-1816-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验